Please ensure Javascript is enabled for purposes of website accessibility

Md. genomic analysis company to remain listed on Nasdaq

(Erwin Wodicka / Depositphotos.com)

(Erwin Wodicka / Depositphotos.com)

OpGen Inc., a Gaithersburg-based computer genomic analysis company, received notification from Nasdaq that it will continue to be listed and traded on the Nasdaq stock market. The company had been in danger of being delisted because its stock price had been too low.

Also, Nasdaq told the company that it complies with listing standards of the Nasdaq Capital Market, and that its Feb. 8 hearing before the Nasdaq Hearings Panel has been canceled.

The stock was trading MOnday afternoon at $2.77 a share, down about 6 percent from its opening price of $2.95 a share.

 


To purchase a reprint of this article, contact reprints@thedailyrecord.com.